NCR1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, despite the well-established observations that CML patients have a decreased expression of NK receptors at diagnosis (36–39), our results confirm that NK cells from TKI-treatment CML patients can express NK activating receptors (40, 41) such as NKp30, NKp46, and NKp80, although this expression is heterogeneous and in some cases their levels are lower than those found in age-matched healthy controls.